News UK's Levicept builds case for osteoarthritis therapy at ACR New data on Levicept's LEVI-04 in patients with osteoarthritis support its potential to become the first new systemic treatment in over two decades.
News Levicept says non-opioid drug cuts arthritis pain in phase 2 A non-opioid drug for pain developed by UK biotech Levicept, with a new mechanism of action, has shown it can reduce pain associated with osteoarthritis in a phase 2 trial.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.